What is the appropriate management for a 17-year-old male with juvenile idiopathic arthritis on adalimumab (Humira) who presents with a paronychia of the second and third toes of the right foot, spreading erythema to the toe bases, pain on walking, dystrophic nails, and is currently prescribed oral cephalexin (Keflex)?

Management of Paronychia in an Immunosuppressed JIA Patient on Adalimumab

This patient requires immediate reassessment with consideration for broader-spectrum antibiotic coverage, possible surgical intervention, and temporary holding of adalimumab until the infection is controlled. Oral cephalexin alone is likely inadequate given the spreading infection, dystrophic nails suggesting possible fungal co-infection, and significant immunosuppression from TNF-inhibitor therapy.

Critical Immunosuppression Context

This 17-year-old on adalimumab faces substantially elevated infection risk. TNF inhibitors like Humira carry serious infection warnings, including bacterial, fungal, and opportunistic pathogens 1. The FDA label explicitly warns that most patients developing serious infections were on concomitant immunosuppressants, and infections can present atypically in immunocompromised hosts 1. The 2008 biologics guidelines emphasize that serious infections, including opportunistic ones, warrant TNF inhibitor discontinuation 2.

Immediate Management Steps

1. Reassess Infection Severity

• Examine for systemic signs: fever, lymphangitic streaking, lymphadenopathy
• Assess for deeper tissue involvement (cellulitis, abscess formation, osteomyelitis)
• Document exact extent of erythema with marking/photography
• Check inflammatory markers (CBC, ESR, CRP) given immunosuppression may blunt typical responses

2. Obtain Cultures Before Antibiotic Escalation

• Bacterial culture and sensitivity from any purulent drainage
• Consider fungal culture given dystrophic nails and chronic nature
• Blood cultures if any systemic symptoms present

3. Antibiotic Management

Keflex monotherapy is insufficient here. The spreading erythema despite oral cephalexin suggests:

• Possible resistant organisms (MRSA is common in paronychia)
• Inadequate tissue penetration
• Polymicrobial infection including anaerobes
• Fungal co-infection

Recommended antibiotic approach:

• Add MRSA coverage immediately: trimethoprim-sulfamethoxazole DS twice daily OR doxycycline 100mg twice daily
• If significant cellulitis or systemic symptoms: consider hospitalization for IV antibiotics (vancomycin plus piperacillin-tazobactam)
• Duration: minimum 10-14 days, longer if slow response

4. Address Dystrophic Nails

The dystrophic nails raise concern for onychomycosis, which occurs in immunosuppressed patients 3. Fungal nail infection can complicate bacterial paronychia and impede healing.

• Obtain nail clippings for fungal culture and KOH preparation
• If onychomycosis confirmed: terbinafine 250mg daily for 12 weeks (preferred in immunosuppressed patients per guidelines) 3
• Monitor liver function tests given concurrent immunosuppression 3

5. Surgical Evaluation

Given pain with walking and spreading infection:

• Urgent podiatry or hand surgery consultation
• May require incision and drainage if abscess present
• Partial nail plate removal if nail bed involvement or dermatophytoma 4
• Debridement of necrotic tissue

6. Adalimumab Management

Hold the next adalimumab dose until infection controlled 1. The FDA label states: "Discontinue HUMIRA if a patient develops a serious infection" 1. While this paronychia may not yet qualify as "serious," the spreading nature in an immunosuppressed host warrants caution.

• Resume adalimumab only after:
  • Complete resolution of erythema and pain
  • Completion of antibiotic course
  • Normal inflammatory markers
  • Rheumatology consultation regarding timing

7. Preventive Measures Going Forward

Once infection resolves, implement strategies to prevent recurrence 4:

• Proper nail trimming technique (straight across, not too short)
• Avoid trauma to nail folds
• Keep feet dry; absorbent cotton socks
• Well-fitting shoes to avoid pressure
• Consider prophylactic antifungal powder in shoes if onychomycosis confirmed
• Regular podiatry follow-up

Monitoring Parameters

• Clinical reassessment in 48-72 hours
• If worsening: hospitalize for IV antibiotics and surgical evaluation
• If improving: continue oral antibiotics, recheck in 1 week
• Document infection resolution before restarting adalimumab
• Screen for other infection sources given immunosuppression

Common Pitfalls to Avoid

1. Underestimating infection severity in immunosuppressed patients - they may not mount typical inflammatory responses
2. Continuing TNF inhibitors during active spreading infection - increases risk of serious complications
3. Missing fungal co-infection - dystrophic nails should trigger fungal workup
4. Inadequate MRSA coverage - community-acquired MRSA is prevalent in skin/soft tissue infections
5. Premature resumption of adalimumab - ensure complete infection resolution first

Coordination of Care

Contact the patient's rheumatologist immediately to:

• Discuss holding adalimumab
• Assess JIA disease activity off medication
• Plan for monitoring and medication resumption
• Consider whether this infection pattern suggests need for alternative immunosuppression strategy

The 2019 ACR/Arthritis Foundation JIA guidelines support continuing biologics with appropriate monitoring 5, but active spreading infections require temporary cessation per drug labeling 1.